

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-143

MICROBIOLOGY REVIEW

SEP 17 1999

JUL 27 1999

Microbiology ReviewDivision of Special Pathogens and Immunologic Drug Products(HFD-590)

NDA# 21-143

Reviewer : Linda Gosey
Correspondence Date : 6-16-99
CDER Receipt Date : 6-17-99
Review Assigned Date: 7-02-99
Review Complete Date: 7-12-99

Sponsor: Taro Pharmaceuticals Inc.
130 East drive
Bramalea, Ontario

Submission Reviewed: Original

Drug Category: Vaginal antifungal


Indication: Treatment of vulvovaginal candidiasis

Dosage Form: 2% vaginal cream

Product Names:

- a. Proprietary:
- b. Nonproprietary: clotrimazole
- c. Chemical: 1H-imidazole, 1-[(2-chlorophenyl)diphenylmethyl]

Structural Formula:



Supporting Documents: NDA 20-574

NDA 21-143
2% clotrimazole crm/VVC
Taro Pharmaceuticals

Summary and Conclusions:

In NDA 20-574 three clinical trials were conducted to assess the efficacy of 2% clotrimazole cream as a 3 day regimen for the treatment of vulvovaginal candidiasis (VVC). In one of the clinical trials the 2% clotrimazole cream that was used was manufactured by Schering-Plough. The two percent clotrimazole cream manufactured by Taro Pharmaceuticals was used in the second clinical trial. A third trial was conducted to assess the bioequivalence of the two products as the formulations of the two clotrimazole creams were slightly different. In 1998, the 2% clotrimazole cream manufactured by Schering-Plough was approved for the treatment of VVC.

In this NDA, #21-143, Taro Pharmaceuticals is seeking approval of their 2% clotrimazole cream as a 3 day treatment regimen for VVC. This application is for over-the-counter (OTC) use only. This supplement contains chemistry, manufacturing controls and labeling sections of the application. The microbiology review of the preclinical and clinical data can be found in document NDA 20-574.0.

Therefore, the reviewing microbiologist recommends approval of this NDA pending final approval of the label.

Recommendations:

There are no microbiology comments to be conveyed to the sponsor at this time.

/S/

Linda L. Gosey
Microbiologist (HFD 590)

Concurrences:

HFD-590/Dep Dir ___
HFD-590/Micro TL ___

/S/

Signature 7/17/99 Date
Signature 7/22/99 Date

CC:

HFD-590/ Orig.NDA#21-143
HFD-590/ Division File
HFD-590/MO
HFD-590/CSO:Chi
HFD-590/Chem
HFD-590/Pharm
HFD-590/Review Micro:Gosey

REVIEW FOR HFD-590
 OFFICE OF NEW DRUG CHEMISTRY
 MICROBIOLOGY STAFF
 MICROBIOLOGIST'S REVIEW #1 OF NDA

January 13, 2000

- A. 1. NDA 21-143 Amendment BC
- SPONSOR Taro Pharmaceuticals
 Five Skyline Drive
 Hawthorne, NY 10532
2. PRODUCT NAMES: Clotrimazole
3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: 2% Vaginal Cream
4. METHOD(S) OF STERILIZATION: NA
5. PHARMACOLOGICAL CATEGORY: Antimicrobial
6. DRUG PRIORITY CLASSIFICATION: S
- B. 1. DATE OF INITIAL SUBMISSION:
2. DATE OF AMENDMENT: December 20, 1999
3. RELATED DOCUMENTS: none
4. ASSIGNED FOR REVIEW: January 10, 2000
- C. REMARKS: This review evaluates the sponsors answers to CMC Microbiology deficiencies.

D. CONCLUSIONS: This submission is recommended for approval on the basis of product quality microbiology.

/S/

1-13-00

Bryan Riley, Ph.D.

PWC

1/14/00

cc: Original NDA 21-143
HFD 590/Consult File
HFD 590/C. Chi
HFD 590/D. Mateka
HFD 805/Consult File
HFD 805/B. Riley

Drafted by: B. Riley, 1/13/00
R/D initialed by: P. Cooney,

**APPEARS THIS WAY
ON ORIGINAL**